W. Todd Penberthy, PhD

Investigators at the Mount Sinai School of Medicine, Toronto, Canada, have been working on a potential correlation for aggressiveness and/or disease-free survival in thyroid cancer patients.

Researchers have posited that well-differentiated thyroid cancers harbor distinct molecular pathological profiles that may be useful as prognostic indicators of future aggressiveness.

While medullary thyroid cancer is not common as other thyroid cancers, it does have a poorer prognosis than these more common forms of metastatic thyroid cancer.

BRAF V600E is essential to the survival of many tumors and has been the focus of targeted therapeutics like a new BRAF V600E-selective inhibitor, which has been used for papillary thyroid carcinomas.

Keith Bible, MD, PhD, Mayo Clinic professor of oncology goes into detail about the current status of using VEGFR tyrosine kinase inhibitors to treat thyroid cancer.

Dr. Nicole O. Vietor presented a report assessing practice discordances related to previously published guidelines published from the American Thyroid Association and the American Association of Clinical Endocrinologists.

Patients in a lenvatinib treatment arm with radioiodine-refractory differentiated thyroid cancer and certain metastasis experienced a much better overall median progression-free survival compared with a placebo arm.